nirmatrelvir
Selected indexed studies
- Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19. (N Engl J Med, 2022) [PMID:35172054]
- Nirmatrelvir Plus Ritonavir: First Approval. (Drugs, 2022) [PMID:35305258]
- Nirmatrelvir/ritonavir (Paxlovid®). (, 1994) [PMID:36378910]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Nirmatrelvir Plus Ritonavir: First Approval. (2022) pubmed
- Paxlovid (Nirmatrelvir/Ritonavir): A new approach to Covid-19 therapy? (2023) pubmed
- Nirmatrelvir/ritonavir for COVID-19: an overview of systematic reviews. (2024) pubmed
- Oral Nirmatrelvir-Ritonavir as Postexposure Prophylaxis for Covid-19. (2024) pubmed
- Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19. (2022) pubmed
- Nirmatrelvir/ritonavir (Paxlovid®). (1994) pubmed
- Nirmatrelvir/ritonavir (Paxlovid®). (1994) pubmed
- [Nirmatrelvir/ritonavir (Paxlovid®), a treatment for Covid-19]. (2022) pubmed
- Nirmatrelvir plus ritonavir in COVID-19: a profile of its use. (2023) pubmed
- Nirmatrelvir for Vaccinated or Unvaccinated Adult Outpatients with Covid-19. (2024) pubmed